drugset / Trial / NCT01211275
Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the effects of axitinib, a potent angiogenesis inhibitor, on tissue and clinical outcome in combination with chemotherapy given to patients with mesothelioma
Timeline
- Start
- 2009-05-22
- Primary completion
- 2012-11-13
- Completion
- 2013-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |